CJC-1295 + Ipamorelin: What the Research Shows

CJC-1295 and Ipamorelin are synthetic peptides frequently studied together because they stimulate the body's natural growth hormone production through two distinct but complementary biological pathways. While research shows this combination can amplify growth hormone pulses in laboratory settings, both compounds remain experimental research chemicals that are not approved for human medical use.

What is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). In the human body, naturally occurring GHRH is produced by the hypothalamus and signals the pituitary gland to synthesize and release growth hormone. However, natural GHRH has an extremely short half-life of just a few minutes before it is broken down by enzymes in the bloodstream. To understand what peptides actually are in this context, it helps to look at their structure: CJC-1295 was engineered by modifying the first 29 amino acids of natural GHRH to resist enzymatic degradation, allowing it to remain active in the body for much longer.

When reviewing the literature on this compound, researchers must distinguish between two distinct versions: CJC-1295 with DAC and CJC-1295 without DAC.

The Drug Affinity Complex (DAC) is a chemical modification—specifically a lysine-maleimide linker—added to the peptide chain. This linker allows the peptide to covalently bind to serum albumin, a highly abundant protein in the blood. Because albumin is a large molecule that circulates for a long time, the attached CJC-1295 is protected from clearance by the kidneys. As a result, CJC-1295 with DAC has a half-life of approximately six to eight days, creating a continuous, sustained elevation of growth hormone and insulin-like growth factor 1 (IGF-1).

CJC-1295 without DAC, frequently referred to in research as Modified GRF 1-29, lacks this albumin-binding linker. Without the DAC modification, the peptide cannot bind to blood proteins and is cleared from the system much faster. Its half-life is approximately 30 minutes. Researchers typically utilize the no-DAC version when they want to study acute, pulsatile releases of growth hormone that more closely mimic the body's natural physiological rhythms, rather than a constant, sustained elevation.

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide, meaning it is composed of a chain of five amino acids. It belongs to a class of compounds known as growth hormone secretagogues (GHS) and functions as a selective ghrelin receptor agonist. Ghrelin, often called the "hunger hormone," naturally binds to specific receptors in the pituitary gland to trigger the release of growth hormone. Ipamorelin mimics this action, binding to the same receptors to initiate a growth hormone pulse.

What makes Ipamorelin particularly notable in scientific literature is its high degree of selectivity. Earlier generations of growth hormone-releasing peptides, such as GHRP-2 and GHRP-6, successfully stimulated growth hormone but also caused significant off-target effects. Specifically, those older compounds often triggered the release of adrenocorticotropic hormone (ACTH), which subsequently spiked cortisol (a stress hormone) and prolactin levels.

Ipamorelin was specifically developed to eliminate these off-target effects. In laboratory and animal models, it has been shown to induce a robust release of growth hormone without causing statistically significant elevations in cortisol or prolactin. This selectivity makes it an attractive compound for researchers who want to isolate the effects of growth hormone signaling without confounding variables introduced by stress hormone fluctuations.

Why researchers study CJC-1295 Ipamorelin combinations

The endocrine system regulates growth hormone through a complex feedback loop involving multiple signals. To maximize growth hormone secretion in laboratory models, researchers often utilize a two-pronged approach, which is why the CJC-1295 and Ipamorelin explained synergy is so frequently cited in peptide literature.

These two peptides operate on entirely different receptors and utilize different intracellular mechanisms. CJC-1295 binds to the GHRH receptor on pituitary somatotropes. When activated, this receptor increases intracellular cyclic AMP (cAMP), which primarily signals the cell to synthesize more growth hormone and prepare it for release.

Ipamorelin, on the other hand, binds to the ghrelin receptor (GHS-R1a). Activation of this receptor increases intracellular calcium levels, which acts as the trigger for the cell to immediately release its stored growth hormone into the bloodstream. Furthermore, ghrelin agonists like Ipamorelin actively suppress somatostatin, a hormone that normally acts as the "stop" signal to halt growth hormone release.

When researchers administer these compounds together, the effects are not merely additive; they are synergistic. CJC-1295 increases the total volume of growth hormone available in the pituitary, while Ipamorelin simultaneously triggers its release and blocks the hormone that would normally stop the process. In animal models, this combination results in a much larger, more robust pulse of growth hormone than either peptide could achieve on its own.

What the research says

In a clinical trial evaluating CJC-1295 with DAC in healthy adults, researchers found that a single injection increased growth hormone levels for up to six days and IGF-1 levels for up to eleven days. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I (IGF-I) secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

Early in vitro and animal studies on Ipamorelin demonstrated that it successfully stimulated growth hormone release with a potency similar to GHRP-6, but without significantly elevating ACTH or cortisol levels. Ipamorelin, the first selective growth hormone secretagogue

A pharmacokinetic study of Ipamorelin in healthy human volunteers confirmed that the peptide rapidly induced growth hormone release with a half-life of approximately two hours. Pharmacokinetics and pharmacodynamics of ipamorelin, a growth hormone secretagogue, in healthy volunteers

Animal research investigating Ipamorelin's effects on bone health found that regular administration increased bone mineral content and bone strength in adult female rats. Ipamorelin, a highly selective growth hormone secretagogue, increases bone mass and strength in rats

A proof-of-concept trial explored Ipamorelin for managing postoperative ileus in bowel resection patients, finding it was well-tolerated but did not significantly accelerate gastrointestinal recovery times compared to a placebo. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients

Human evidence — and its limits

While the mechanisms of these peptides are well-documented in cellular and animal models, high-quality human evidence remains strictly limited. The foundational data for CJC-1295 comes from a Phase I/II dose-escalation study published in 2006. In that study, doses ranging from 30 to 60 micrograms per kilogram of body weight were used to establish the peptide's pharmacokinetic profile and safety in healthy volunteers. However, this study only evaluated the DAC version of the peptide over a short duration. There are no large-scale, long-term human trials evaluating the safety or efficacy of CJC-1295 without DAC (Modified GRF 1-29).

Similarly, while Ipamorelin has been tested in humans—most notably in clinical trials attempting to treat postoperative ileus—it ultimately did not demonstrate enough clinical efficacy to warrant FDA approval for that condition. The human trials that do exist for Ipamorelin generally feature small sample sizes, short durations, and highly specific patient populations.

Crucially, there are no peer-reviewed, published human clinical trials evaluating the combination of CJC-1295 and Ipamorelin. The synergistic effects observed in the combination are extrapolated entirely from basic science, animal models, and the known pharmacological profiles of the individual receptors. Because long-term human data is absent, researchers do not yet know the optimal dosing parameters, the potential for pituitary receptor desensitization over time, or the long-term health impacts of artificially manipulating the growth hormone axis with these specific synthetic analogs.

Safety and regulatory status

Neither CJC-1295 nor Ipamorelin is approved by the U.S. Food and Drug Administration (FDA) or any other global regulatory body for human medical use. They are classified strictly as experimental research chemicals. Furthermore, because they stimulate growth hormone production, both compounds are banned by the World Anti-Doping Agency (WADA) and most major sporting organizations.

In laboratory settings, these peptides are typically supplied as lyophilized (freeze-dried) powders that require careful handling and precise peptide reconstitution using bacteriostatic water before they can be utilized in in vitro or animal studies.

Because they are not approved pharmaceuticals, the safety profiles of these compounds are incomplete. Theoretical risks based on their mechanisms of action include water retention, joint pain, decreased insulin sensitivity (as growth hormone naturally antagonizes insulin), and the potential for pituitary feedback suppression. The long-term safety of sustained growth hormone elevation via synthetic secretagogues remains unknown.

Key takeaways

• CJC-1295 is a synthetic GHRH analog that signals the pituitary to synthesize growth hormone; it exists in a long-acting form (with DAC) and a short-acting form (without DAC).
• Ipamorelin is a selective ghrelin receptor agonist that triggers the immediate release of growth hormone without significantly spiking cortisol or prolactin.
• Researchers frequently study these two peptides together because they act on different receptors, creating a synergistic effect that produces a larger growth hormone pulse than either compound alone.
• While often discussed alongside the best peptides for recovery in theoretical literature, human clinical data on this specific combination is virtually non-existent.
• Both CJC-1295 and Ipamorelin are strictly experimental research chemicals, are not approved for human use by the FDA, and lack long-term safety data.

Frequently asked questions

What is the difference between CJC-1295 DAC and no DAC?

CJC-1295 with DAC contains a chemical linker that binds to blood proteins, extending its half-life to several days for sustained growth hormone elevation. CJC-1295 without DAC (Modified GRF 1-29) lacks this linker, resulting in a short half-life of about 30 minutes that mimics natural, pulsatile hormone release.

Why are CJC-1295 and Ipamorelin used together in research?

They are used together because they target two different biological pathways. CJC-1295 increases the synthesis of growth hormone via the GHRH receptor, while Ipamorelin triggers its release and blocks inhibitory signals via the ghrelin receptor, resulting in a synergistic effect.

Does Ipamorelin increase cortisol or prolactin?

Unlike older growth hormone secretagogues such as GHRP-2 or GHRP-6, Ipamorelin is highly selective. Research indicates that it stimulates growth hormone release without causing statistically significant increases in cortisol or prolactin levels.

Is CJC-1295 approved for human use?

No. CJC-1295 is an experimental research chemical that has not been approved by the FDA or any other regulatory agency for human medical use. It is legally available only for laboratory and preclinical research purposes.